VETOQUINOL Aktie

 

Annual sales: €526 m (+0.2% at constant exchange rates) Essential Products sales: €334 m (+4.1% at constant exchange rates) EBIT before amortization of acquired assets: €92 m (17.4% of sales) Net result, Group share: €57 m (10.9% of sales) Cash flow generation: €72 mLURE, France--(BUSINESS WIRE)--Regulatory News: Commenting on the 2025 fiscal year, Matthieu Frechin, Chairman and CEO of Vetoquinol (Paris:VETO), stated, “In an extremely volatile environment, Vetoquinol has once again this year demonstrated the resilience of its business model, driven by a long-term strategic vision which, combined with our proactive management of expenses, enables us to deliver a healthy level of profitability. We will actively pursue this strategy, relying in particular on the territory expansion of our Essentials.” The Board of Directors of Vetoquinol SA, meeting on March 25, 2026, reviewed the company's performance and approved the financial statements for the 2025 fiscal year. The audit procedures are cur...

Annual sales: €526 million (up 0.2% at constant exchange rates and down 2.5% on a reported basis) Annual sales of Essential Products: €334 million (up 4.1% at constant exchange rates and up 2.1% on a reported basis)LURE, France--(BUSINESS WIRE)--Regulatory News: In an economy marked by unusual exchange rate volatility, Vetoquinol (Paris:VETO) achieved two important objectives: growth in Essential products and internalization of the manufacturing of the parasiticide range. Vetoquinol's sales for FY 2025 came to €525.7 million, up 0.2% at constant exchange rates and down 2.5% on a reported basis. Over the financial year, the company recorded historically high negative currency impacts of €14.8 million in all territories except Europe and a significant impact from the simplification of the Complementary product ranges of -€9.7 million. Net of these two items, sales for the 2025 financial year were up 2.1% compared with 2024. Sales of Essential Products totaled €334.5 million, up 4.1% at constant...

9-month sales: €384 million (-1.3% at constant exchange rates and -3.5% on a reported basis) 9-month sales of Essential products: €244 million (64% of sales, +2.7% at constant exchange rates and +1.1% on a reported basis)LURE, France--(BUSINESS WIRE)--Regulatory News: At the end of September 2025, Vetoquinol's (Paris:VETO) sales amounted to €384.2 million, down 3.5% on a reported basis and down 1.3% at constant exchange rates. Over this period, the Group recorded net negative currency impacts of €8.9 million in the Americas and Asia-Pacific/Rest of the World regions and an impact of - €7.7 million from the simplification of complementary ranges, mainly in Europe. Net of these two items, sales for the first nine months of 2025 were up +0.7% compared to the previous year. Sales of Essential products totaled €244.2 million, up 1.1% on a reported basis and 2.7% at constant exchange rates. The performance of Essentials in the 3rd quarter is relative and can be explained by the ongoing transfer of ...

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

Sales: €258m (-1.0% at constant exchange rates) Essential products sales: €165m (+4.2% at constant exchange rates) Net income, Group share: €25m (9.7% of sales) EBITDA: €53m (20.4% of sales) Cash flow generation: €51mLURE, France--(BUSINESS WIRE)--Regulatory News: The Board of Directors of Vetoquinol SA (Paris:VETO), meeting on September 9, 2025, approved the financial statements for the first half of the 2025 financial year. The limited review report on the financial statements as of June 30, 2025, was issued by the Statutory Auditors. Vetoquinol's sales amounted to €258 million for the first six months of fiscal year 2025. Sales of Essentials products amounted to €165 million, up 4.2% at constant exchange rates, representing 64% of the Group's sales for H1 2025, compared with 60% in H1 2024. Essentials continue to grow at a sustained pace. On a reported basis, the 2.6% decline in sales compared with the previous fiscal year reflects the continued simplification of Complementary products,...

Das Instrument 8JM FR0004186856 VETOQUINOL INH. EO 2,50 EQUITY wird ex Dividende/Zinsen gehandelt am 04.06.2025 The instrument 8JM FR0004186856 VETOQUINOL INH. EO 2,50 EQUITY has its ex-dividend/interest day on 04.06.2025...

Das Instrument 8JM FR0004186856 VETOQUINOL INH. EO 2,50 EQUITY wird cum Dividende/Zinsen gehandelt am 03.06.2025 und ex Dividende/Zinsen am 04.06.2025 The instrument 8JM FR0004186856 VETOQUINOL INH. EO 2,50 EQUITY has its pre-dividend/interest day on 03.06.2025 and its ex-dividend/interest day on 04.06.2025...

Essential products sales: €85m (+1.8% at constant exchange rates and on a reported basis) LURE, France--(BUSINESS WIRE)--Regulatory News: Vetoquinol Group (Paris:VETO): First-quarter sales of Essential products totaled 85 million euros, up+ 1.8% at constant exchange rates. Sales of Essential products in Q1 2025 continued to grow in all territories outside the USA. Europe, the Group's largest market, grew by over 3%, the Americas (excluding the USA) by over 4%, and Asia-Pacific/Rest of the World posted strong growth of close to 25% at constant exchange rates. The United States was down sharply, penalized by a wait-and-see market and the slower-than-expected return to normal sales of the range unavailable in 2024. At the same time, the Group is pursuing its rationalization program for non-critical complementary ranges, which automatically led to a drop in sales of these products of around €2.0 million in Q1 In Q1 2025, sales of Essential products represented 65% of Vetoquinol's sales. Overall, on a re...

Annual sales: €539m (+2.2% at constant exchange rates) Essential products sales: €328m (+4.6% at constant exchange rates) Net result, Group share: €59m (10.9% of sales) EBITDA: €104m (19.3% of sales) Cash flow generation: €86m LURE, France--(BUSINESS WIRE)--Regulatory News: Matthieu Frechin, Chairman and CEO of Vetoquinol (Paris:VETO), commented: "In 2024, we delivered a solid financial year, combining growth in almost all our reference markets, high profitability and sustained cash generation. We have achieved this performance while absorbing the sometimes significant uncertainties, such as in the United States this year, as well as the cost of transforming the Group. This is due to the strength of our model built around Essentials, which have achieved an annual average growth above 8% since 2014, and to our reactive management, which enables us to adapt quickly to changing economic conditions. We will therefore actively pursue the implementation of this strategy in 2025, while paying part...